Edition:
United States

Sunesis Pharmaceuticals Inc (SNSS.OQ)

SNSS.OQ on NASDAQ Stock Exchange Capital Market

0.63USD
11:24am EDT
Change (% chg)

$-0.00 (-0.32%)
Prev Close
$0.63
Open
$0.64
Day's High
$0.68
Day's Low
$0.60
Volume
80,705
Avg. Vol
169,823
52-wk High
$2.59
52-wk Low
$0.24

Latest Key Developments (Source: Significant Developments)

Sunesis Pharmaceuticals Reports Qtrly Loss Per Share $0.10
Wednesday, 8 May 2019 04:05pm EDT 

May 8 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.SUNESIS PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.10.  Full Article

Sunesis Pharmaceuticals Inc - Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard - SEC Filing
Friday, 11 Jan 2019 05:58pm EST 

Jan 11 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS PHARMACEUTICALS INC - NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD - SEC FILING.SUNESIS PHARMACEUTICALS - IS CONSIDERING ACTIONS THAT IT MAY TAKE TO REGAIN COMPLIANCE WITH CONTINUED LISTING REQUIREMENTS..  Full Article

Sunesis Pharmaceuticals Reports Q3 Loss Per Share $0.18
Monday, 5 Nov 2018 04:05pm EST 

Nov 5 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.QTRLY LOSS PER SHARE $0.18.Q3 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S.  Full Article

Sunesis Pharmaceuticals Qtrly Loss Per Share $0.21
Tuesday, 8 May 2018 04:00pm EDT 

May 8 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q1 REVENUE $200,000 VERSUS I/B/E/S VIEW $200,000.QTRLY LOSS PER SHARE $0.21.  Full Article

Sunesis Pharma Qtrly Loss Per Share $0.21
Thursday, 8 Mar 2018 04:05pm EST 

March 8 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.QTRLY LOSS PER SHARE $0.21.Q4 EARNINGS PER SHARE VIEW $-0.29 -- THOMSON REUTERS I/B/E/S.  Full Article

Sunesis Pharmaceuticals Inc - Daniel Swisher Resigns As CEO Effective End Of 2017
Monday, 4 Dec 2017 04:05pm EST 

Dec 4 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS PHARMACEUTICALS INC - DANIEL SWISHER RESIGNS AS CEO EFFECTIVE END OF 2017.SUNESIS PHARMACEUTICALS INC - SWISHER TO REMAIN WITH SUNESIS AS A STRATEGIC ADVISOR.SUNESIS PHARMACEUTICALS INC - BOARD MEMBER DAYTON MISFELDT APPOINTED INTERIM CEO EFFECTIVE JANUARY 2018.  Full Article

Sunesis Pharmaceuticals Appoints William Quinn As CFO
Thursday, 30 Nov 2017 07:00am EST 

Nov 30 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS PHARMACEUTICALS APPOINTS WILLIAM QUINN AS CHIEF FINANCIAL OFFICER AND SENIOR VICE PRESIDENT, FINANCE AND CORPORATE DEVELOPMENT.SUNESIS PHARMACEUTICALS INC - ‍WILLIAM QUINN MOST RECENTLY SERVING AS CEO AND CO-FOUNDER OF PRIVATE CANCER IMMUNOTHERAPY COMPANY BULLET BIOTECHNOLOGY​.  Full Article

Sunesis Pharmaceuticals Inc Q3 loss per share ‍$0.43​
Thursday, 2 Nov 2017 07:00am EDT 

Nov 2 (Reuters) - Sunesis Pharmaceuticals Inc :Sunesis Pharmaceuticals reports third quarter 2017 financial results and recent highlights.Sunesis Pharmaceuticals Inc qtrly loss per share ‍$0.43​.Sunesis Pharmaceuticals Inc- ‍pro-forma Sept 30, 2017 cash, cash equivalents and marketable securities of $37.1 million is expected to fund co into 2019​.  Full Article

Sunesis announces pricing of $20 million offering of securities
Wednesday, 25 Oct 2017 08:54am EDT 

Oct 25 (Reuters) - Sunesis Pharmaceuticals Inc ::Sunesis announces pricing of $20 million offering of securities.Sunesis Pharmaceuticals Inc - pricing of underwritten public offerings of 7.5 million shares and accompanying warrants to purchase 3.8 million shares​.Sunesis Pharmaceuticals- ‍also priced 2,500 shares of non-voting series D convertible preferred stock, accompanying warrants to purchase 1.3 million shares​.  Full Article

Sunesis Pharmaceuticals announces proposed public offering of common stock, preferred stock and warrants
Tuesday, 24 Oct 2017 04:05pm EDT 

Oct 25 (Reuters) - Sunesis Pharmaceuticals Inc :Sunesis announces proposed public offering of common stock, preferred stock and warrants.Sunesis Pharmaceuticals Inc - ‍anticipates using net proceeds from proposed offerings to fund development of sns-062, additional kinase inhibitor programs​.  Full Article